AXA S.A. - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 199 filers reported holding DENALI THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.3%.

Quarter-by-quarter ownership
AXA S.A. ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$7,313,933
-30.8%
354,529
-1.1%
0.03%
-25.7%
Q2 2023$10,575,853
+58.7%
358,382
+23.9%
0.04%
+52.2%
Q1 2023$6,664,136
-17.3%
289,242
-0.2%
0.02%
-20.7%
Q4 2022$8,062,675
-47.2%
289,920
-41.7%
0.03%
-3.3%
Q3 2022$15,269,813
+4.7%
497,544
+0.4%
0.03%
+11.1%
Q2 2022$14,579,546
+13.0%
495,382
+23.5%
0.03%
+50.0%
Q1 2022$12,904,273
+31.5%
401,136
+82.3%
0.02%
-28.0%
Q4 2021$9,815,000
-3.5%
220,066
+9.2%
0.02%
-13.8%
Q3 2021$10,170,000
-64.5%
201,580
-44.8%
0.03%
-29.3%
Q2 2021$28,662,000
+183.6%
365,400
+106.5%
0.04%
+32.3%
Q1 2021$10,105,000
-23.7%
176,978
+11.9%
0.03%
-26.2%
Q4 2020$13,250,000
+65.8%
158,190
-29.1%
0.04%
+44.8%
Q3 2020$7,993,000
-26.6%
223,071
-50.5%
0.03%
+38.1%
Q2 2020$10,890,000
+65.5%
450,380
+19.8%
0.02%
+31.2%
Q1 2020$6,582,000375,9240.02%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q3 2022
NameSharesValueWeighting ↓
Crestline Management, LP 7,460,732$240,012,00028.78%
Casdin Capital, LLC 1,500,000$48,255,0002.16%
Flagship Pioneering Inc. 2,619,968$84,284,0001.98%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 38,000$8,192,0001.85%
Yiheng Capital Management, L.P. 1,014,684$32,642,0001.49%
SECTORAL ASSET MANAGEMENT INC 207,100$6,662,0001.18%
Artal Group S.A. 600,000$19,302,0000.81%
GILDER GAGNON HOWE & CO LLC 2,619,217$84,260,0000.78%
Temasek Holdings (Private) Ltd 5,369,487$172,736,3970.73%
BRANDYWINE MANAGERS, LLC 9,601$309,0000.53%
View complete list of DENALI THERAPEUTICS INC shareholders